Search Search by keyword Filter Diseases & Conditions — ADHDAlzheimer’s DiseaseAmyloidosisAmyotrophic Lateral SclerosisAnemia in Chronic Kidney DiseaseAsthmaAtopic DermatitisAtrial FibrillationBehavioral HealthBeta ThalassemiaBladder CancerBreast CancerCancerCardiac & Vascular DiseaseChemotherapy-Induced NeutropeniaChronic PainColorectal CancerCommunity HealthCOVID-19Cystic FibrosisDiabetesDuchenne Muscular DystrophyECMOEndometriosisHeart FailureHemophilia AHemophilia BHepatitis CHereditary AngioedemaHigh CholesterolHypertrophic CardiomyopathyLeukemia and LymphomaLung CancerLupus NephritisMethods Update: Ultra-Rare DiseaseMethods Update: Value Assessment FrameworkMethods Update: Valuing A CureMigraineMultiple MyelomaMultiple SclerosisMyasthenia GravisNASHObesity ManagementOpioid EpidemicOsteoporosisOvarian CancerPalliative CarePeanut AllergyPolicy: Accelerated Approval PathwayPolicy: Fair AccessPolicy: Gene TherapiesPolicy: Indication Specific PricingPolicy: Orphan Drug Policy ReformPolicy: Real World EvidencePolicy: RebatesPolicy: Unsupported Price IncreasePolicy: Value Assessment and International Reference PricingProstate CancerPsoriasisPTSD: Service DogsRetinal DiseaseRheumatoid ArthritisSickle Cell DiseaseSleep ApneaSpinal Muscular AtrophyTardive DyskinesiaUlcerative Colitis Status — Ongoing Completed Year Completed — 20072008200920102011201220132014201520162017201820192020202120222023 Research Type — AssessmentPolicy Paper Results: Ongoing & Completed Policy Papers Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage Apr 2022 Unsupported Price Increases Occurring in 2021 Dec 2022 Unsupported Price Increases Occurring in 2020 in California Oct 2022 PTSD: Service Dogs Fair Access: Coverage Policies in 2020 Dec 2021 Unsupported Price Increases Occurring in 2020 Nov 2021 Value Assessment and International Reference Pricing Sep 2021 Strengthening the FDA’s Accelerated Approval Pathway Apr 2021 Unsupported Price Increases Occurring in 2019 Jan 2021 Cornerstones of ‘Fair’ Drug Coverage Sep 2020 Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19 Jul 2020 Methods Update: Value Assessment Framework Jan 2020 Unsupported Price Increases Occurring in 2017-2018 Oct 2019 Methods Update: Valuing a Cure Sep 2019 Alternative Models for Pharmaceutical Rebates Dec 2018 A Framework to Guide the Optimal Development and Use of Real World Evidence for Coverage and Formulary Decisions Dec 2017 Methods Update: Treatments for Ultra-Rare Diseases May 2017 Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value Dec 2016 Indication-specific pricing: pharmaceuticals in the United States health care system Dec 2015 Alzheimer’s Disease: Evaluating Diagnostics Dec 2012
